How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?
Conditions: Glaucoma, Open-Angle; Glaucoma; Drugs Interventions: Drug: dorzolamide/timolol Sponsors: CT Glaucoma Associates Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
Conditions: Primary Open-angle Glaucoma Interventions: Drug: TimoD implant; Device: Injector system Sponsors: EyeD Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Phase 2 Trial Evaluating Travoprost Ophthalmic Topical Cream in Subjects With Open-angle Glaucoma or Ocular Hypertension
Conditions: Open Angle Glaucoma; Ocular Hypertension Interventions: Drug: Travoprost Ophthalmic Topical Cream low-dose; Drug: Travoprost Ophthalmic Topical Cream mid-dose; Drug: Travoprost Ophthalmic Topical Cream high-dose; Drug: Timolol maleate ophthalmic solution, 0.5%; Drug: Travoprost Ophthalmic Solution, 0.004% Sponsors: Glaukos Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
Conditions: Open Angle Glaucoma; Ocular Hypertension Interventions: Drug: Travoprost Ophthalmic Topical Cream low-dose; Drug: Travoprost Ophthalmic Topical Cream mid-dose; Drug: Travoprost Ophthalmic Topical Cream high-dose; Drug: Timolol maleate ophthalmic solution, 0.5%; Drug: Travoprost Ophthalmic Solution, 0.004% Sponsors: Glaukos Corporation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
Timolol for TKI Induced Paronychia
Conditions: Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both) Interventions: Drug: Topical Timolol Sponsors: Queen Mary Hospital, Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
Conditions: Cataract; Glaucoma; Ocular Hypertension Interventions: Drug: Bimatoprost Implant System (High Dose); Drug: Bimatoprost Implant System (Low Dose); Drug: Timolol Maleate Ophthalmic Solution, 0.5%; Device: Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL; Device: SpyGlass IOL Sponsors: SpyGlass Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
Conditions: Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glaucoma, Unspecified Eye; Ocular Hypertension (OHT) Interventions: Drug: Experimental: QLS-111 ophthalmic solution, (0.015%); Drug: Experimental: QLS-111 ophthalmic solution, (0.03%); Drug: Experimental: QLS-111 ophthalmic solution, (0.075%); Drug: Timolol maleate Preservative Free 0.5% ophthalmic solution; Other: QLS-111 ophthalmic vehicle solu tion Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials
